Mesothelin enhances ovarian cancer invasion by MMP-7 expression through the MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) and JNK (c-Jun N-terminal kinase) signal transduction pathways. This evidence concerns the gene WNK2 and ovarian carcinoma.